Summary
Alzheimer’s
Disease (AD) is an irreversible, progressive neurodegenerative disease,
characterized by cognitive impairment, memory loss and functional decline.
Symptoms typically begin to first occur in patients in their mid-sixties,
appearing in varying stages. The pathological features of AD comprise
histopathological changes within the brain. Mild Cognitive Impairment (MCI) is
a heterogeneous condition between normal cognition and dementia, whereby
cognitive changes in mental abilities, such as memory or thinking, are
affected. Almost all cases of AD begin with MCI, but it should be noted that
not all patients with MCI go on to develop AD.
Although
there is a high degree of failure and uncertainty within the R&D of AD
drugs, the number of drugs in the pipeline is considerable, at 559. The
majority of the pipeline products are novel, and there are only seven
repositioned drugs and five generic drugs. This shows progression in terms of
the different molecules being developed as therapeutic agents within the AD
pipeline.
Access This Full Report @ http://www.radiantinsights.com/research/Alzheimers-therapeutics-in-asia-pacific-markets
Scope
The
AD market has a lack of therapeutic options.
- Which classes of drug dominate the market?
- What newly approved therapies have entered
the market?
- How do the leading marketed therapies
compare clinically?
- How will the new therapies be positioned in
the treatment of AD?
- How have selected late-stage pipeline
therapies performed in clinical trials?
The
pipeline contains a range of molecule types and molecular targets, including
those that are well established in AD, and novel, first-in-class therapies.
- Which molecular targets appear most
frequently in the pipeline?
AD
clinical trials have an overall attrition rate of 94%.
- What are the failure rates for individual
Phases of clinical development?
- How do AD clinical trial characteristics,
including failure rate, duration, and size compare against respiratory and
industry averages?
Download sample Copy of This Report at: http://www.radiantinsights.com/research/Alzheimers-therapeutics-in-asia-pacific-markets#tabs-4
The
AD market is forecast to rise from a value of $3 billion in 2014 to $5.1
billion in 2021, at a CAGR of 7.9% across the four Asia-Pacific markets
assessed.
- How much of a role will disease prevalence
and new product approvals play in market growth?
- Will generic competition have a significant
impact on the market over the forecast period?
There
have been 170 licensing deals and 104 co-development deals pertaining to AD
products since 2006.
- Which territories show the most deal
activity?
- What were the trends in deal completion by
product stage of development?
- What were the conditions of the key
licensing or co-development deals to take place in AD?
See More Reports of This Category
by Radiant Insights:
·
China Respiratory Disposables Market Outlook to 2021
- http://www.radiantinsights.com/research/china-respiratory-disposables-market-outlook-to-2021
·
China Respiratory Measurement Devices Market Outlook
to 2021 - http://www.radiantinsights.com/research/china-respiratory-measurement-devices-market-outlook-to-2021
Reasons to buy
This
report will allow you to -
- Understand the current clinical and
commercial landscape through a comprehensive study of disease pathogenesis,
diagnosis, prognosis, and the current treatment algorithm used in AD.
- Assess the safety and efficacy of current
treatment options, with extensive product profiles on prominent marketed
therapies, and a heatmap directly comparing safety and efficacy data.
- Analyze the AD pipeline and stratify by
stage of development, molecule type, and molecular target. The most promising
late-stage therapies are profiled and assessed in terms of clinical performance
and competitiveness, alongside a single-product forecast.
- Predict growth in market size in four
Asia-Pacific markets, with in-depth market forecasting from 2014 to 2021. The
forecasts will provide an understanding of how epidemiology trends, new drug
entries, and patent expirations will influence market value.
- Identify commercial opportunities in the AD
deals landscape by analyzing trends in licensing and co-development deals, and
by profiling the most significant deals that have occurred in this indication
in recent years.
About Radiant Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More Information, Visit Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog URL: http://www.radiantinsightsinc.blogspot.com
No comments:
Post a Comment